Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completed

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

NCT04295005
completed

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

NCT03918148

Clinical Trials (2)

Showing 2 of 2 trials
NCT04295005

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Completed
NCT03918148

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2